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Abstract
Hypothyroidism is a condition that results from thyroid hormone deficiency 
that can range from an asymptomatic condition to a life-threatening disease. The 
prevalence of hypothyroidism varies according to the population, from up to 3 to 
4% in some populations and in the case of subclinical hypothyroidism up to 5–10%. 
Clinical symptoms of hypothyroidism are diverse, broad, and non-specific and can 
be related to many systems, reflecting the systemic effects of thyroid hormones. 
The severity of the symptoms is usually related to the severity of the thyroid hor-
mone deficit. The most common form of hypothyroidism, primary hypothyroid-
ism, is diagnosed when there is elevation of TSH and decrease in the level of free 
T4 and Subclinical hypothyroidism is diagnosed when there is an elevation of TSH 
with normal levels of free T4. The most frequent cause of primary hypothyroid-
ism in populations without iodine deficiency is Hashimoto’s thyroiditis or chronic 
lymphocytic thyroiditis. Iodine deficiency is the main cause of hypothyroidism in 
populations with deficiency of iodine intake.  The treatment of choice for hypothy-
roidism is thyroxine (T4), which has shown efficacy in multiple studies to restore 
the euthyroid state and improve the symptoms of hypothyroidism. In subclinical 
hypothyroidism, the treatment depends on the age, functionality, and comorbidi-
ties of the patients. The total replacement dose of levothyroxine in adults is approxi-
mately 1.6 mcg/kg;  however in elderly patients with heart disease or coronary heart 
disease, the starting dose should be from 0.3 to 0.4 mcg/kg/day with progressive 
increase of 10% of the dose monthly.
Keywords: hypothyroidism, autoimmune, Hashimoto’s disease, thyroxine, 
thyroid diseases
1. Introduction
Hypothyroidism is a common disease in many populations, and prevalence var-
ies depending on the sex and the age of the population studied, the iodine status of 
the population, and the cut points used to define overt and subclinical hypothyroid-
ism [1–11].
Hypothyroidism is 10 times more prevalent in women than in men [2]. It is 
more prevalent in the elderly people, ranging from 2 to 5% of the population. 
In iodine-sufficient populations, hypothyroidism ranges from 1 to 2%, while in 
iodine deficient areas, the prevalence can be as high as 3–4% [2–14]. Prevalence in 
the USA in the Colorado trial can range from 0.3% and 3.7%, while in Europe can 
be 0.2 and 5.3% [12].
The prevalence of subclinical hypothyroidism is even higher; in one of the larg-
est studies in the USA, it reaches 9% of the population [12].
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2. Physiology
Thyroid word comes from the Greek shield because of its shape. The weight 
is from 10 to 20 g. Changes of thyroid shape and volume are dependent on age 
and sex. In the adult population, the usual length is 40–60 mm and the diameter 
13–18 mm. The volume is 10–15 ml for females and 12–18 ml for males [15, 16].
The thyroid gland is composed of functional secretory units known as follicles 
where thyroid hormones are synthetized and storage in the follicular cells and the 
lumen of the follicles where colloid is stored. The colloid contains high amounts of 
thyroglobulin (Tg), a 660 kDa glycoprotein, where thyroid hormones are stored [17].
Thyroid hormones are composed by an inner ring, the tyrosine molecule, and 
the outer ring with a phenyl ring. The active forms of thyroid hormones are thy-
roxine or T4, with four iodine atoms, and triiodothyronine or T3, with three iodine 
atoms. Under physiologic states, 90% of thyroid gland output is T4 and 10% is T3. 
The half-life of thyroid hormones is of few hours for T3 and 7 days for T4 [17].
The follicular cells contain a sodium iodide active symporter responsible for 
iodine transport against a concentration gradient to synthesize thyroid hormones; 
it can increase iodine concentration in the follicular cell by more than 20 times 
above the serum concentration. Iodine is then transported by pendrin in the apical 
membrane to the colloid in a passive manner [17].
Iodine must be organified to be attached to the tyrosine residues of thyroglobu-
lin. The thyroid peroxidase (TPO) is the enzyme of the selenoprotein group, with 
hydrogen peroxide organifying iodine to thyroglobulin. Once in the colloid, iodine is 
organifid  to thyroglobuline to produce, monoiodothyrosine and diiodothyrosine wich 
finally are coupled to produce T4 and T3, this process is catalyzed by the TPO [17].
TPO activity is regulated by iodine concentration and can be blocked by an 
excess of iodine concentration, which is known as the Wolff-Chaikoff effect and 
can lead to a temporary hypothyroidism with an escape mechanism. On the other 
side, an iodine-depleted thyroid gland that is exposed to iodine can increase 
thyroid synthesis, which is known as the Jod-Basedow effect, and lead to hyper-
thyroidism [17].
TPO is the enzyme related to autoimmune hypothyroidism as most of the 
patients have positive anti-TPO antibodies [16, 17].
2.1 Regulation of thyroid hormones production
Thyroid hormone production is regulated by the hypothalamus pituitary axis. 
At the hypothalamus, thyrotropin-releasing hormone (TRH) is produced. TRH 
stimulates the pituitary to produce thyroid-stimulating hormone (TSH) [17].
What trigger thyroid hormone synthesis and release is the stimulation of the 
TSH in the basolateral receptor of the follicular cell, which is a receptor of the seven 
transmembrane domain G protein-coupled receptors proteins. The effects of the 
TSH receptor in the follicular cells are derived to the increased concentration in 
intracellular cyclic adenosine monophosphate (cAMP) that results in increased 
iodine uptake and increased protein synthesis to enhance the production of thyroid 
hormones as well as produce a trophic effect at the thyroid gland [17].
3. Definitions
Hypothyroidism is a condition that results from thyroid hormone deficiency 
which can range from an asymptomatic condition to a life-threatening condition of 
the patient life [17–19].
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Hypothyroidism can be primary due to a decrease in the production of thyroid 
hormones in the thyroid gland, secondary due to deficit in the production of 
TSH in the pituitary or tertiary due to a deficit in the production of TRH in the 
hypothalamus.
3.1 Subclinical hypothyroidism
Subclinical hypothyroidism is a biochemical diagnosis in which there is an eleva-
tion of TSH with a normal level of free thyroid hormones in plasma.
4. Manifestations of hypothyroidism
4.1 Adults
Clinical symptoms of hypothyroidism are diverse, broad, and neither sensitive 
nor specific to make the diagnosis of hypothyroidism and can be related to many 
systems, reflecting the systemic effects of thyroid hormones. The severity of the 
symptoms is usually related to the severity of the thyroid hormone deficit.
Systemic symptoms include lethargy, cold intolerance, goiter, and weight gain. 
At the cardiovascular system hypothyroidism can produce bradycardia, cardiac 
failure, angina, and pericardial effusion. Gastrointestinal symptoms are constipa-
tion and ileus, neuromúscular manifestations include myalgia, hoarse voice, slow 
relaxing reflexes, depression, emotional lability, psychosis an carpal tunnel syn-
drome. Hematologic changes include macrocytic anemia, pernicious anemia, and 
iron deficiency anemia. Skin manifestations include, myxoedema, hair loss, and 
coarse skin. In the reproductive system menorrhagia and infertility and finally, 
hyperlipidaemia as the main metabolic manifestation [17–21].
4.2 Myxedema
Myxedema coma is a severe state of hypothyroidism and an endocrine emergency. 
Manifestations are depressed mental state and hypothermia with a hypometabolic state 
with bradycardia. Decreased myocardial contractility and pericardial effusion lead to 
hypotension. Other features are anemia, hyponatremia, and renal dysfunction [22].
4.3 Congenital hypothyroidism
Thyroid hormones are necessary to have a normal neurodevelopment and 
growth. Symptoms and signs of congenital hypothyroidism are goiter, poor feeding, 
macroglossia, prolonged jaundice, developmental delay hypothermia, bradycardia, 
edema, large fontanelles, umbilical hernia, and poor growth [23].
5. Etiology
5.1 Diagnosis
The diagnosis of hypothyroidism is made biochemically. The elevation of TSH 
levels associated with low levels of free T4 confirms the diagnosis of primary hypo-
thyroidism; in this case it is not necessary to measure levels of free T3 or T3 because 
in the state of hypothyroidism the peripheral conversion of T4 to T3 is increased so 
that T4 will be more diminished than T3 [18, 19, 24].
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In secondary hypothyroidism, decreased T4 is found, and TSH is low or normal 
(not elevated), which means that the pituitary is not responding adequately to a 
deficit of thyroid hormones.
Subclinical hypothyroidism is diagnosed in patients with elevated TSH despite hav-
ing normal levels of free T4. These patients may or may not be symptomatic [18, 19, 24].
Although the differential diagnosis in hypothyroidism involves multiple 
pathologies, with symptoms and signs related to hypothyroidism such as anemia 
and hyponatremia, among others, the differential diagnosis must also be among 
the various pathologies that produce hypothyroidism that will be discussed in the 
etiology section [25, 26].
However, it is important to take into account the sick euthyroid syndrome that 
refers to alterations in thyroid function tests that can be found in patients with criti-
cal illness and can vary depending on the severity and duration of the disease.
In laboratory alterations, there is a decrease in T3 and a smaller proportion of T4, 
due to an increase in the activity of reverse T3. Subsequently, there is a progressive 
decrease in TSH followed by a progressive elevation and finally normalization of all 
thyroid function tests once the injury is resolved [25, 26].
6. Differential diagnosis
6.1 Primary hypothyroidism
6.1.1 Chronic autoimmune thyroiditis or Hashimoto’s thyroiditis
It is the most prevalent cause of hypothyroidism in iodine-sufficient countries.
Chronic autoimmune thyroiditis can be goitrous or atrophic. Goitrous hypothy-
roidism is called Hashimoto thyroiditis [27].
More than 90% of patients have elevated anti-thyroglobulin or anti-peroxidase 
(microsomal antigen) or anti-sodium iodine transporter. Antibodies against thyroid 
gland produce chronic autoimmune thyroiditis with lymphocytic infiltration and 
fibrosis, leading to goiter or atrophy of the thyroid gland [27–29].
Women are five times more affected than men. After the age of 45, the rates of 
hypothyroidism increase [27].
Based on one of the most representative studies of the population of the USA 
that included 17,353 people, it found a prevalence of 4.6% of hypothyroidism, 0.3% 
frank hypothyroidism and 4.3% subclinical hypothyroidism [30].
The course of chronic autoimmune thyroiditis is a gradual loss of thyroid 
function. The spectrum ranges from subclinical hypothyroidism with positive 
antibodies to frank hypothyroidism, a process that affects approximately 5% 
patients per year.
The majority of patients present hypothyroidism for life; however it may be 
transient [28].
The risk factors for Hashimoto’s thyroiditis are multiple; the female gender 
and the older age are two risk factors. There is a genetic factor associated with 
multiple polymorphisms in human leukocyte antigen (HLA) genes, T cell 
receptors, and immunomodulatory molecules. Patients with Down or Turner 
syndrome have a higher prevalence. Chronic autonomic thyroiditis can be part of 
the autoimmune type 2 polyglandular syndrome, and affected patients are more 
likely to develop other autoimmune diseases such as diabetes and adrenal insuf-
ficiency [27, 31, 32].
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6.1.2 Iodine deficiency
Iodine deficiency, defined as the daily intake of less than 100 mcg of iodine, is 
the most common cause of hypothyroidism worldwide and the most prevalent cause 
of hypothyroidism in populations with iodine deficiency. As previously described, 
excess iodine can produce hypothyroidism due to Wolff-Chaikoff effect; however 
this effect is usually transient [33, 34].
6.1.3 Iatrogenic disease
Post-thyroidectomy state, radioactive iodine therapy for thyroid cancer, or 
hyperthyroidism and neck radiation at doses greater than 25 Gy are the main 
causes of iatrogenic hypothyroidism, and as the use of these therapies increases, it 
becomes a more prevalent etiology [35, 36].
6.1.4 Drugs
Thionamides, lithium, tetracyclines, thalidomide, ethionamide, and iodine-
containing drugs like amiodarone can cause hypothyroidism. Thyrosine kinase 
inhibitors can cause thyroiditis; sorafenib can produce hypothyroidism by increased 
type 3 deiodination. Immune therapy including pembrolizumab, nivolumab, 
ipilimumab, alemtuzumab, interleukin 2, and interferon alfa can produce hypothy-
roidism [37].
6.1.5 Thyroiditis
6.1.5.1 Subacute or granulomatous thyroiditis
Subacute or granulomatous thyroiditis is an acute inflammation of the thyroid 
gland of viral etiology that presents with hyperthyroidism, followed by hypothy-
roidism and subsequent recovery of thyroid function. Transient hypothyroidism 
usually lasts from a few weeks to a maximum of 3–6 months and may be permanent 
in 5% of patients [38, 39].
The presentation consists of acute pain in the thyroid region that increases 
when swallowing or moving the head and radiates to the jaw. Symptoms may vary 
depending on whether the patient is in the hyperthyroid, euthyroid, or hypothyroid 
category [38, 39].
The findings in thyroid gammagraphy are compatible with thyroiditis due to a 
decrease in iodine uptake diffusely [38, 39].
6.1.5.2 Silent thyroiditis or postpartum thyroiditis
Silent thyroiditis or postpartum thyroiditis corresponds to a thyroiditis of 
autoimmune etiology, which occurs in the first year postpartum. It presents with 
hyperthyroidism in up to 30% of patients, followed by hypothyroidism in up to 
50% of patients; however it can only be present as hypothyroidism or hyperthy-
roidism [40–42].
It is more frequent in patients with type 1 diabetes mellitus and patients with 
positive anti-peroxidase antibodies. The prevalence can reach up to 17%. It has been 
associated with deterioration or onset of postpartum depression. Up to 30% of 
patients remain hypothyroid [40–42].
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6.1.6 Infiltrative diseases
Riedel’s thyroiditis is a fibrosclerosing thyroiditis of unknown etiology, with 
a probable primary anti-immune or fibrotic origin similar to retroperitoneal 
fibrosis, fibrosing mediastinitis, sclerosing cholangitis, and lacrimal fibrosis, 
among others [43, 44].
Riedel’s thyroiditis is characterized by slow, non-painful growth, sensation of 
pressure in the neck, dysphagia, dysphonia, and hypoparathyroidism. From 30 
to 60% of patients present clinical or subclinical hypothyroidism. It is one of the 
IgG4-related disease varieties, together with Fibrosing hashimoto thyroiditis, Igg4-
related Hashimoto’s disease, and Graves’ disease associated with IgG4 [43–45].
Other infiltrative diseases like hemochromatosis, scleroderma, leukemia, 
cystinosis, M. tuberculosis infection, and P. carinii are less frequent causes of 
hypothyroidism.
6.2 Secondary hypothyroidism
Central hypothyroidism is a much less frequent form of hypothyroidism, with a 
prevalence of 1:16,000 to 1:100,000 in the general population. It can be congenital 
or acquired [46].
The causes of acquired central hypothyroidism are usually related to the 
causes of hypopituitarism like a pituitary sellar region mass, usually a pituitary 
adenoma, which produces secondary hypothyroidism by thyrotropic cell com-
pression, or tertiary hypothyroidism with decreased production of TRH by the 
hypothalamus. Other lesions of the sellar region, such as meningiomas, cysts, 
abscesses, metastasis, craniopharyngiomas, and dysgerminomas, can produce 
central hypothyroidism [46, 47].
In addition to space-occupying injuries, radiation with doses greater than 40 
Gray performed for brain, orbital, or nasal lesions can produce central hypothy-
roidism [46, 47].
Other less frequent causes of central hypothyroidism are hypophyseal infiltra-
tive pathologies such as haemochromatosis, sarcoidosis or tuberculosis, cranial 
trauma, Sheehan syndrome, and the use of drugs as checkpoint inhibitors [46, 47].
7. Treatment
7.1 Clinical hypothyroidism
Since the nineteenth century, levothyroxine has been used for the treatment of 
hypothyroidism. Usually hypothyroidism requires treatment with lifelong hormone 
replacement with levothyroxine. In a few cases, transient hormonal substitution 
due to transient secondary hypothyroidism is required, for example, to subacute 
thyroiditis or drug-induced hypothyroidism [48–50].
The treatment of choice is thyroxine (T4), which has shown efficacy in mul-
tiple studies to restore the euthyroid state and improve the symptoms of hypothy-
roidism [51–54].
The goal of treatment of primary hypothyroidism is to take the patient to the 
normal range of TSH. However, the normal range of TSH varies depending on the 
age and population studied. Most people are in the range of 0.5–4.5 mU/L; however 
as the age of people increases, the normal range of TSH increases, leading to values 
of up to 7.0 mU/L in those over 90 years. In contrast, most young and healthy 
patients are in the range of 0.5–2.5 mU/L [50].
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For this reason, in the treatment of hypothyroidism, the dose of levothyroxine 
and the goal of TSH depend on the age of the patient and the comorbidities [49, 50].
Levothyroxine (T4) is a prohormone and requires deionization to T3 which is the 
active form of thyroid hormone. Levothyroxine is absorbed in the small intestine. 
The meal affects the time of maximum concentration, which in normal conditions 
is 2 h. The bioavailability is from 60 to 80%. The metabolism is catabolized by the 
thyroid deionidase enzyme that removes the iodine from carbon 5 of the outer 
ring to transform T4 into T3. Approximately half of T4 is deionized to rT3 (inac-
tive form) and half to T3 (active form). Both T3 and reverse T3 are metabolized to 
diiodothyronine (T2) and monoiodothyronamine (T1) and T2 and T1 reverses [48].
Multiple medications interact with the function or pharmacokinetics of levo-
thyroxine, amiodarone, androgens, calcium carbonate and citrate, carbamazepine, 
cholestyramine, ferrous sulfate, glucocorticoids, orlistat, phenytoin, proton pump 
inhibitors, salicylates, sucralfate, and tamoxifen, which are just some of the medica-
tions that alter bioavailability, metabolism, protein binding, or hormone levels [48].
The total replacement dose of levothyroxine in adults is approximately 1.6 mcg/
kg, given that the body’s requirements for thyroid hormones are proportional 
to weight. In healthy young patients, the starting dose could be 1.6 mcg/kg/day; 
however in elderly patients with heart disease or coronary heart disease, the start-
ing dose should be from 0.3 to 0.4 mcg/kg/day with a progressive increase of 10% 
in the dose every 4–6 weeks [50]. Levothyroxine must be taken with empty stomach 
30–60 min before the next meal, usually, breakfast.
The thyroid function is monitored with TSH at 4–6 weeks after starting treat-
ment. If the TSH goal is not achieved, the dose of levothyroxine should be adjusted 
by increasing or decreasing 10% of the dose ideally, especially in older adults [50].
In the case of secondary hypothyroidism, TSH levels are low or inappropriately 
normal for a low free T4. Therefore, the follow-up is not done with TSH levels but 
with free T4 levels, to achieve a normal level for the reference range.
7.2 Subclinical hypothyroidism
In the case of subclinical hypothyroidism, the treatment also depends on the age, 
functionality, and comorbidities of the patients [50].
For patients younger than 75 years, with TSH greater than 10 mU/L, treatment 
is recommended. However, in those patients with TSH between 4.5 and 10 mU/L, 
treatment depends on the presence of symptoms and especially the presence of 
goiter or anti-TPO antibodies, which predict progression to clinical hypothyroid-
ism [54–56].
In patients older than 75 years, treatment depends on the patient’s frailty and 
should be limited to functional patients with TSH greater than 10 mU/L or patients 
with TSH of 6–10 mU/L in the presence of antithyroid antibodies, symptoms, and 
concomitant diseases in that they can be impaired by hypothyroidism such as heart 
failure. Fragile patients, more than 75 years old, may be advisable to be observed 
without treatment [50].
8. Conclusion
Hypothyroidism is a highly prevalent chronic disease, widely studied by medi-
cal science, with a wide spectrum of severity, ranging from subclinical hypo-
thyroidism to the hypothyroid myxedematous state. In some cases of subclinical 
hypothyroidism, treatment may not be necessary; however in other cases such as 
in myxedematous states, the treatment may be lifesaving. There are multiple trials 
Metabolic Disorders
8
that evaluate the treatment of hypothyroidism in different populations, and there 
is still controversy regarding the treatment of subclinical hypothyroidism in some 
populations. It is very important for the primary care physicians to have a broad 
knowledge of hypothyroidism since they will face hypothyroid patients in the 
day-to-day clinical practice.
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